The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Share News (BMY)

Share Price Information for Bloomsbury (BMY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 576.00
Bid: 570.00
Ask: 576.00
Change: 6.00 (1.05%)
Spread: 6.00 (1.053%)
Open: 564.00
High: 576.00
Low: 564.00
Prev. Close: 570.00
BMY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Riverstone Credit stays stable, Bloomsbury hails record half

Thu, 26th Oct 2023 18:12

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Wednesday and Thursday, and not separately reported by Alliance News:

----------

Riverstone Credit Opportunities Income PLC - London-based energy infrastructure and energy transition credit investor - Net asset value at September 30 was USD1.07, unchanged from June 30. Says this stability was due to continued strong portfolio performance during the third quarter of 2023, and that as of September 30 it is nearly fully invested based on the revolving credit facility added in the fourth quarter last year and on current portfolio commitments. Riverstone Credit says it remains extremely well positioned due to its portfolio of accredited energy-transition focused investments through green or sustainability-linked structured loans. Notes "backdrop of strong energy market performance, the global focus on decarbonisation and the company's unique focus on short duration lending."

----------

Bloomsbury Publishing PLC - London-based publisher - Pretax profit for the half year ended August 31 was up 8% to GBP14.0 million from GBP12.9 million the year before. Says revenue increased 11% to GBP136.7 million from GBP122.9 million, and diluted earnings per share rose 11% to 13.66 pence from 12.30p. Consumer revenue grew 17% to GBP89.4 million, Adult Trade revenue rose 8% to GBP27.6 million and Children's Trade revenue grew 22% to GBP61.7 million. Declares interim dividend of 3.70p per share, more than double 1.41p the prior year. Cash at August 31 totalled GBP39.1 million, down from GBP41.5 million on the same day in 2022. Says it is confident it will achieve market expectations for the year ending February 29 2024, meaning revenue of GBP273.1 million and profit before tax and "highlighted items" of GBP32.5 million.

----------

Schroder Income Growth Fund PLC - UK-based investment company - Lifts dividend for the year ended August 31 by 4.6% to 13.80p per share from 13.20p the year before. Net asset value total return was positive 4.2%, underperforming against positive 5.2% from the FTSE All Share Total Return index. NAV per share decreased to 293.58p from 295.26p. Says many challenges "look set to continue into the year ahead."

----------

Haydale Graphene Industries PLC - Carmarthenshire, Wales-based technology solutions company - Pretax loss for the year ended June 30 widens to GBP6.6 million compared with GBP5.2 million the previous year. Revenue increased 48% to GBP4.3 million from GBP2.9 million, with US sales continuing to progress on "growth in the core aerospace and automotive markets". Administrative expenses increased 13% to GBP6.3 million from GBP5.5 million. Non-Executive Chair David Banks says: "We have made important progress in our next planned steps as a business by forging commercial partnerships and collaborations with leading organisations...the board remains confident that the company will be able to take advantage of the traction it is now seeing."

----------

e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says that in six months ended July 31, pretax loss widened to GBP6.6 million from GBP4.5 million the previous year. Revenue fell 46% to GBP160,000 from GBP295,000. Chief Executive Officer Ali Mortazavi says: "Despite a severe macroeconomic climate, we have made significant progress during the past six months...we have been able to translate our computational analyses into tangible assets, generating compelling preclinical data at a fraction of the R&D spend of any competitor." Research & development expenditure increased to GBP5.3 million from GBP3.1 million. Company expects higher "underlying cash burn" in the current half year due to its "planned increase in R&D spend to continue the expansion of our AI capabilities and progress the identification and execution of preclinical targets, together with sustaining our active IP strategy as novel inventions are generated."

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
26 Mar 2018 21:56

Reuters Health News Summary

Following is a summary of current health news briefs. Biohaven plunges as investors pit migraine data against Allergan's drug Biohaven Pharmaceutical Holding said its acute two a

Read more
26 Mar 2018 13:56

Reuters Health News Summary

Following is a summary of current health news briefs. Singapore pharma on recovery path after worst output in decades Singapore's among

Read more
26 Mar 2018 13:56

Reuters Health News Summary

Following is a summary of current health news briefs. Singapore pharma on recovery path after worst output in decades Singapore's among

Read more
26 Mar 2018 07:23

UPDATE 1-Roche's Tecentriq cocktail notches another lung cancer success

ZURICH, March 26 (Reuters) - Roche's immunotherapy Tecentriq combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss trial

Read more
25 Mar 2018 14:15

Israel to launch Big Data health project

By Maayan Lubell JERUSALEM, March 25 (Reuters) - Israel will invest nearly 1 billion shekels ($287 million) in a to a

Read more
20 Mar 2018 07:05

UPDATE 1-Roche says Tecentriq, chemo cut risk of death in type of lung cancer

ZURICH, March 20 (Reuters) - Roche's immunotherapy Tecentriq plus chemotherapy cut the risk of disease worsening or death in advanced squamous lung cancer, but it did not

Read more
19 Mar 2018 17:59

Bloomsbury Publishing Expecting Profitability To Beat Expectations

LONDON (Alliance News) - Bloomsbury Publishing PLC said on Monday it expects its full-year profit and revenue to both be ahead of expectations.For the year ending 28 to

Read more
20 Jan 2017 09:08

Bloomsbury Publishing Says Chairman Salz To Step Down In July

Read more
27 Oct 2016 07:43

Bloomsbury Publishing Sees Stronger Second Half As Trading In Line

Read more
13 Jul 2016 12:55

Bloomsbury Publishing plots expansion into B2B market

(ShareCast News) - Harry Potter publisher Bloomsbury Publishing held a capital markets day for investors and analysts on Wednesday to present plans to enter the business-to-business market, while also confirming first-quarter trading remained in line with full year expectations. Bloomsbury unveiled

Read more
13 Jul 2016 08:20

Bloomsbury Publishing Says Full Year Trading To Meet Expectations

Read more
12 Jul 2016 15:11

UK Shareholder Meetings Calendar - Next 7 Days

Read more
8 Jul 2016 15:00

UK Shareholder Meetings Calendar - Next 7 Days

Read more
19 May 2016 12:43

Bloomsbury moves towards digital B2B after strong FY

(ShareCast News) - Bloomsbury, the publisher behind the Harry Potter phenomenon, has turned in an overall strong set of full-year results and launched a 2020 strategy to move into digital B2B publishing. It booked a full-year pretax profit of £10.36m, from a year-earlier profit of £9.60m, with reven

Read more
19 May 2016 08:18

Bloomsbury To Reoganise Divisions As Profit Lifted By Children's Books

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.